FORMULATION ARTICLES
-
![biotechnology, Global Networking, Research, Development, Innovation, Advancing Smart Solutions-GettyImages-2123154659]( "Innovations In The Oligonucleotide Supply Chain: Regulatory Considerations For Materials, Manufacturing, And Lifecycle Control")
Innovations In The Oligonucleotide Supply Chain: Regulatory Considerations For Materials, Manufacturing, And Lifecycle ControlOligonucleotide therapeutics have rapidly advanced into late-stage and commercial development, shifting regulatory focus toward the maturity of manufacturing and supply chain control rather than therapeutic novelty. Regulatory success now depends on how effectively sponsors translate innovative chemistries into well-characterized, scalable, and sustainable materials and processes.
-
![GettyImages-1459917555-lab-research-development-gene-genetic]( "The mRNA Supply Chain Revolution: Materials, Methods, And Momentum")
The mRNA Supply Chain Revolution: Materials, Methods, And MomentummRNA innovation now hinges as much on manufacturing materials as on molecular design, with novel inputs shaping performance, cost, and scalability. As these less-mature materials move rapidly into production, strategic material selection and supplier alignment are becoming critical to manufacturing resilience and long-term success.
-
![genetic research, biotechnology, molecular biology, innovation, healthcare solutions-GettyImages-2234236209]( "A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?")
A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.
-
![Scientist virus research laboratory-GettyImages-1493597834]( "2026 Outlook: How Modality Maturity, Delivery, And Data Will Reshape RNA Therapeutics")
2026 Outlook: How Modality Maturity, Delivery, And Data Will Reshape RNA TherapeuticsAs RNA therapeutics mature, 2026 will reward execution over novelty. Delivery, data-driven design, and modality specialization will determine which RNA platforms scale clinically and commercially.
-
![DNA genetic research-GettyImages-2151457031]( "Designing mRNA For The Next Generation Of Therapeutics")
Designing mRNA For The Next Generation Of TherapeuticsmRNA’s next leap goes beyond vaccines. This piece explores how tuning sequence design, structure, and longevity enables controlled protein expression for cancer, rare disease, and regenerative uses.
-
![Genetic engineering-GettyImages-1133966737]( "The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs")
The Great Cell Therapy Reset: Solving The Industrial Math Of Living DrugsThe cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).
FORMULATION VIDEOS
Discover key strategies for controlling LNP formulation and upscaling. Explore the science behind lipid nanoparticles, critical parameters, and achieving effective turbulent mixing for optimal outcomes.
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.
As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Lowering The Lipid Barrier To RNA-LNP Therapeutics")
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.
-
![GettyImages-1807380795-analytics-cell-analysis-laboratory]( "Oligonucleotide Purification And Synthesis")
Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.
-
![Crispr gene editing-GettyImages-1139760176]( "CRISPR 101 - Your Guide To Understanding CRISPR")
Review the fundamentals of CRISPR technology, development, and its use to manipulate genes in different ways, such as altering their nucleotide sequences or changing their expression.
-
![GettyImages-1087219020 Scientists wearing protective coveralls working in manufacturing laboratory]( "Insights Into GMP Manufacturing Of RNA-LNP Drug Products")
Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, and strategic collaborations.
-
![GettyImages-1358868801 antibodies]( "How mRNA Technology Engineers Next-Generation Antibodies")
Monoclonal antibodies (mAbs) stand as pivotal drug products and biochemical reagents in the 21st century. Explore how mRNA-encoded antigens could revolutionize antibody discovery.
-
![GettyImages-1305685152 vaccine]( "The Heroes Of Vaccine Development: Lipid Nanoparticles")
Lipid nanoparticles (LNPs) have played a crucial role in COVID-19 vaccine development as efficient mRNA delivery systems, exhibiting versatility and effectiveness in accelerating the process.
-
![Treatment with Nanoparticles Genetic therapy GettyImages-805434264]( "Process Development Considerations For RNA-LNP Therapeutics")
Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).
